{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:33:48Z","timestamp":1787002428242,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/hr.2016.96","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T02:01:58Z","timestamp":1469671318000},"page":"907-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data"],"prefix":"10.1038","volume":"39","author":[{"given":"Shinzo","family":"Hiroi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"BFhr201696_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253\u2013390.","journal-title":"Hypertens Res"},{"key":"BFhr201696_CR2","unstructured":"The 2010 National Health and Nutrition Survey in Japan. The Ministry of Health, Labour, and Welfare. Tokyo, Japan, 2012. In Japanese \n                    http:\/\/www.mhlw.go.jp\/bunya\/kenkou\/eiyou\/h22-houkoku.html\n                    \n                  . Accessed 15 March 2016."},{"key":"BFhr201696_CR3","unstructured":"Miura K . (chief investigator) Comprehensive research business on strategies to prevent\/treat cardiovascular disease\/lifestyle-related diseases such as diabetes mellitus by a scientific grants\/subsidy from the Ministry of Health, Labour and Welfare, \u2018Research on the start of follow-up of the subjects of the 2010 National Health and Nutrition Survey (NIPPON DATA2010) and continuation of NIPPON DATA80\/90 follow-up\u2019, Comprehensive\/project study reports in 2012. 2013. Japanese."},{"key":"BFhr201696_CR4","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1253\/circj.CJ-13-0847","volume":"77","author":"K Miura","year":"2013","unstructured":"Miura K, Nagai M, Ohkubo T . Epidemiology of hypertension in Japan: where are we now? Circ J 2013; 77: 2226\u20132231.","journal-title":"Circ J"},{"key":"BFhr201696_CR5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(11)61055-6","volume":"378","author":"N Ikeda","year":"2011","unstructured":"Ikeda N, Saito E, Kondo N, Inoue M, Ikeda S, Satoh T, Wada K, Stickley A, Katanoda K, Mizoue T, Noda M, Iso H, Fujino Y, Sobue T, Tsugane S, Naghavi M, Ezzati M, Shibuya K . What has made the population of Japan healthy? Lancet 2011; 378: 1094\u20131105.","journal-title":"Lancet"},{"key":"BFhr201696_CR6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1751-7176.2010.00360.x","volume":"12","author":"AH Gradman","year":"2010","unstructured":"Gradman AH . Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010; 12: 869\u2013878.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFhr201696_CR7","first-page":"HC25","volume":"8","author":"B Bhushan","year":"2014","unstructured":"Bhushan B, Gupta S, Khajuria V, Kumar D, Lal M, Kumar D, Bhat S, Sharma A . Comparative efficacy and safety of triple therapy (Ramipril, telmisartan, hydrochlorothiazide) vs dual antihypertensive therapy (Ramipril or telmisartan, hydrochlorothiazide) in stage 2 hypertensive patients. J Clin Diagn Res 2014; 8: HC25\u2013HC28.","journal-title":"J Clin Diagn Res"},{"key":"BFhr201696_CR8","first-page":"1477","volume":"72","author":"N Sato","year":"2014","unstructured":"Sato N, Hasebe N . Fixed-drug combinations for hypertension. Nihon Rinsho 2014; 72: 1477\u20131484 (in Japanese).","journal-title":"Nihon Rinsho"},{"key":"BFhr201696_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/hr.2012.216","volume":"36","author":"T Kohro","year":"2013","unstructured":"Kohro T, Yamazaki T, Sato H, Ohe K, Nagari R . The impact of a change in hypertension management guidelines on diuretic use in Japan: trends in antihypertensive drug prescriptions from 2005 to 2011. Hypertens Res 2013; 36: 559\u2013563.","journal-title":"Hypertens Res"},{"key":"BFhr201696_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.","journal-title":"BMJ"},{"key":"BFhr201696_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/hr.2014.144","volume":"38","author":"T Ogihara","year":"2015","unstructured":"Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Teramukai S, Higaki J, Ito S, Shimada K COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res 2015; 38: 89\u201396.","journal-title":"Hypertens Res"},{"key":"BFhr201696_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/hr.2014.141","volume":"38","author":"T Saruta","year":"2015","unstructured":"Saruta T, Ogihara T, Saito I, Rakugi H, Shimamoto K, Matsuoka H, Teramukai S, Higaki J, Ito S, Shimada K . Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res 2015; 38: 132\u2013136.","journal-title":"Hypertens Res"},{"key":"BFhr201696_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/hr.2014.164","volume":"38","author":"S Kim-Mitsuyama","year":"2015","unstructured":"Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OSCAR Study Group. Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study. Hypertens Res 2015; 38: 199\u2013207.","journal-title":"Hypertens Res"},{"key":"BFhr201696_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","volume":"58","author":"SV Badve","year":"2011","unstructured":"Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, Tonkin A, Perkovic V . Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 1152\u20131161.","journal-title":"J Am Coll Cardiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr201696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201696","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:17:23Z","timestamp":1684415843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFhr201696"],"URL":"https:\/\/doi.org\/10.1038\/hr.2016.96","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"assertion":[{"value":"18 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SH, YS and TK are current employees of Takeda Pharmaceutical Company. YO and KI are current employees of Milliman. MO has received financial support for research from Daiichi Sankyo Company, Boehringer Ingelheim, Takeda Pharmaceutical Company, MSD KK, Kyowa Hakko Kirin, Kowa Pharmaceutical Company, Teijin Home Healthcare, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan, Bristol-Myers Squibb, Sumitomo Dainippon Pharma, Mochida Pharmaceutical, Actelion Pharmaceuticals Japan, Otsuka Pharmaceutical, Teijin Pharma and Genzyme Japan KK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}